Liang-Ke Mm Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Liang-Ke Mm Tang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Guobo Du
Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
2 shared publications Dai-Yuan Ma
Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
1 shared publication- Jing Zhou
Affiliated Hospital of North Sichuan Medical College
1 shared publication - Tao Li
Department of Oncology, People's Hospital of Nanbu County, Nanchong, China
1 shared publication - Tingting Jia
Affiliated Hospital of North Sichuan Medical College, Department of Oncology, Nanchong, China
1 shared publication Ya-Lang Mm Xiang
Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
1 shared publication
Latest Publications
- Open Access
- 6 November 2023
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 90 (1) , 101358
miR-186 regulates epithelial–mesenchymal transformation to promote nasopharyngeal carcinoma metastasis by targeting ZEB1
- 6 November 2023
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 90 (1) , 101358
Open AccessmiR-186 regulates epithelial–mesenchymal transformation to promote nasopharyngeal carcinoma metastasis by targeting ZEB1
- Open Access
- 28 July 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (30) , e34349
Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report
Rationale: Multiple primary malignant tumors are rare and challenging to diagnose. Diffuse malignant peritoneal mesothelioma (DMPM) originate from the peritoneum, which lacks specific clinical manifestations and is difficult to diagnose, with a short survival about 10 to 13 months for inoperable ones. This is the first report of metachronous double primary malignant tumors in nasopharyngeal carcinoma and DMPM accompanied with paraneoplastic syndromes. Patient concerns: A 61-year-old man presented with abdominal discomfort with a history of nasopharyngeal carcinoma 5 years ago. Diagnoses: The diagnosis of DMPM was finally confirmed by laparoscopic mesenteric biopsies. Paraneoplastic syndromes including increased platelets were present when diagnosis, followed by increased neutrophils after disease progression. Interventions: Due to intolerable for surgery, he was treated with pemetrexed combined with nivolumab, intraperitoneal infusion of nivolumab, radiotherapy, anlotinib and maintenance treatment of nivolumab. Outcomes: Progression-free survival in first line is 12 months, overall survival is 23 months. Lessons: This indicate that comprehensive treatment including immunotherapy may be helpful for inoperable DMPM patients with nasopharyngeal carcinoma accompanied with paraneoplastic syndromes.
- 28 July 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (30) , e34349
Open AccessMetachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report
Rationale: Multiple primary malignant tumors are rare and challenging to diagnose. Diffuse malignant peritoneal mesothelioma (DMPM) originate from the peritoneum, which lacks specific clinical manifestations and is difficult to diagnose, with a short survival about 10 to 13 months for inoperable ones. This is the first report of metachronous double primary malignant tumors in nasopharyngeal carcinoma and DMPM accompanied with paraneoplastic syndromes. Patient concerns: A 61-year-old man presented with abdominal discomfort with a history of nasopharyngeal carcinoma 5 years ago. Diagnoses: The diagnosis of DMPM was finally confirmed by laparoscopic mesenteric biopsies. Paraneoplastic syndromes including increased platelets were present when diagnosis, followed by increased neutrophils after disease progression. Interventions: Due to intolerable for surgery, he was treated with pemetrexed combined with nivolumab, intraperitoneal infusion of nivolumab, radiotherapy, anlotinib and maintenance treatment of nivolumab. Outcomes: Progression-free survival in first line is 12 months, overall survival is 23 months. Lessons: This indicate that comprehensive treatment including immunotherapy may be helpful for inoperable DMPM patients with nasopharyngeal carcinoma accompanied with paraneoplastic syndromes.